Form 4: Corcept Therapeutics Director Exercises Options and Sells Shares Under 10b5-1 Plan

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Summary

• On April 10, 2025, Daniel N. Swisher Jr., a director of Corcept Therapeutics, exercised stock options to acquire 2,200 shares of common stock at a price of $12.13 per share.
• Simultaneously, Swisher sold 2,200 shares of common stock at $70.22 per share.
• These transactions were executed under a 10b5-1 trading plan adopted on August 1, 2024.
• Following these transactions, Swisher directly owns 0 shares of Corcept Therapeutics common stock.
• Swisher also holds 1,800 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's prospects or strategy. It is common for executives and directors to use 10b5-1 plans to diversify their holdings and avoid accusations of insider trading.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance.
• The use of a 10b5-1 plan is a common practice among corporate insiders to manage their stock holdings in compliance with securities laws.
• Comparable companies such as Exelixis, Halozyme Therapeutics, and Incyte Corporation also have executives and directors who regularly file Form 4s to report their transactions.

Stakeholder Impact

• The transactions have a minimal impact on stakeholders as they are part of a pre-arranged trading plan and do not reflect a change in the director's long-term view of the company.

Key Dates

Keywords

Form 4, Corcept Therapeutics, CORT, Daniel N. Swisher Jr., Stock Options, 10b5-1 Plan, Insider Trading, Director, Share Sale